Most leukemia diagnoses lead straight into treatment. Chronic lymphocytic leukemia (CLL) is different. Many people are diagnosed incidentally, after an abnormal blood count. They feel completely fine, and then get monitored, sometimes for years, before treatment ever comes up.
This approach, known as watch and wait or active surveillance, is based on decades of clinical evidence: having the disease and needing treatment are not the same. Treatment starts once CLL shows measurable signs of progression. Targeted therapies can achieve durable disease control, but randomized evidence still supports observation for patients who don’t meet established treatment criteria.
CLL: What Does Progression Look Like?
Chronic lymphocytic leukemia is mainly a disease of older adults, with a median age at diagnosis of about 70 years. In the United States, around 5 people per 100,000 are diagnosed each year. Many have no symptoms when CLL is first found, more than 80% of cases have been reported as being discovered incidentally.
CLL develops when a clone of mature B lymphocytes begins to accumulate in the blood, bone marrow, lymph nodes, and spleen. The cells survive longer than normal B cells, also supported by signals from their surrounding microenvironment. Over time, the size and distribution of this clone can change considerably.
As CLL expands, it can interfere with normal blood-cell production in the bone marrow, causing anemia or low platelet counts. Accumulation in lymph nodes and the spleen can lead to enlargement, sometimes causing discomfort or a feeling of fullness.
More active disease can produce fatigue, unexplained weight loss, fever, and night sweats. CLL also disrupts normal immune function, raising infection risk even before treatment begins. It can trigger autoimmune complications too, most commonly autoimmune hemolytic anemia and immune thrombocytopenia.
What Does “Watch and Wait” Actually Mean?
The aim is to avoid exposing patients to treatment toxicity when earlier therapy hasn’t been shown to improve survival. Patients remain under active surveillance, with follow-up focused on blood counts, lymphocyte trends, lymph node and spleen enlargement, symptoms, and changes in the overall disease course.
A rising lymphocyte count may lead to closer monitoring without requiring treatment. Mild thrombocytopenia that remains stable can carry a different significance from a platelet count that progressively falls. Changes over time often provide more useful information.
Considering immune dysfunction, preventive care, vaccination, infection awareness, and appropriate cancer screening are important. There is also no established diet, supplement, or lifestyle change that has been shown to prevent CLL progression or delay the need for treatment.
When Does CLL Actually Need Treatment?
The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria help distinguish measurable leukemia from disease that is beginning to affect the patient:
Falling hemoglobin or platelet counts. Hemoglobin below 10 g/dL or a platelet count below 100 × 10⁹/L are commonly used thresholds, but a stable platelet count below that threshold doesn’t automatically trigger treatment, and other causes of cytopenia need to be considered.
Enlarging lymph nodes or spleen. Treatment may become necessary when lymphadenopathy or splenomegaly is massive, progressively enlarging, or causing symptoms.
Rapidly increasing lymphocyte counts. Lymphocyte increase of at least 50% over two months or a lymphocyte doubling time of less than six months, once other factors that can raise lymphocyte counts have been ruled out. A markedly elevated absolute lymphocyte count on its own is not sufficient.
CLL-related symptoms. Significant constitutional symptoms: unintentional weight loss, substantial fatigue, persistent fever without infection, and prolonged night sweats without another explanation. Other indications are symptomatic extranodal involvement and autoimmune anemia or thrombocytopenia that responds poorly to corticosteroids.
You can also read:
Why Not Treat CLL Before These Problems Develop?
The idea of treating CLL earlier has been studied for decades. Trials using older treatment approaches (including FCR chemoimmunotherapy regimen) failed to establish a survival advantage for treating asymptomatic early-stage disease.
Targeted therapy made it relevant again. BTK inhibitors can produce prolonged disease control, raising the question of whether giving one before symptoms develop could alter CLL’s natural course. The phase III CLL12 trial provided a test of that strategy.
What Did the CLL12 Trial Show About Early Treatment?
CLL12 enrolled patients with previously untreated, asymptomatic Binet stage A CLL who were considered at increased risk of progression. A total of 363 patients were randomized to receive ibrutinib or placebo, and 152 patients classified as low risk were followed in a watch-and-wait cohort.
Early ibrutinib significantly delayed progression to symptomatic disease, with a hazard ratio of 0.276 compared with placebo. Yet after a median observation time of 69.3 months, no overall survival benefit was demonstrated. Estimated five-year survival was 93.3% with ibrutinib and 93.6% with placebo. Cardiovascular toxicity was increased with ibrutinib.
CLL12 does not settle every possible early-intervention strategy. The ongoing phase III EVOLVE CLL/S1925 trial is testing a different one: fixed-duration venetoclax plus obinutuzumab given early versus the same regimen delayed until standard iwCLL treatment criteria are met, in patients with asymptomatic high-risk CLL or small lymphocytic lymphoma. Overall survival is the primary endpoint. The study remains active.
What If CLL Has High-Risk Genetic Features?
Genetic and molecular features such as del(17p), TP53 mutations, and unmutated IGHV can predict disease behavior and prognosis, with major implications for treatment selection once treatment is needed. Current evidence doesn’t support using genetic risk alone as an indication for early treatment.
A 2026 genetic analysis of CLL12 looked at whether particular molecular subgroups benefited from early ibrutinib. Several genetic abnormalities were associated with shorter event-free survival in the placebo group, confirming their prognostic importance, but no genetic subgroup showed an overall survival benefit. Patients with del(17p) or TP53-mutated asymptomatic CLL didn’t show an event-free survival benefit from early ibrutinib either.
Does Everyone With CLL Eventually Need Treatment?
No. Some people with CLL remain stable without treatment for many years, and a proportion may never need CLL-directed therapy. The course can vary widely, even among patients who initially have early, symptom-free disease.
One of the strongest biological markers is IGHV mutation status, with unmutated IGHV generally following a more active course and a shorter time to first treatment. The International Prognostic Score for Early-stage CLL (IPS-E) is deliberately simple: one point each for unmutated IGHV, a lymphocyte count above 15 × 10⁹/L, and palpable lymph nodes. In the study that developed and validated it across almost 5,000 patients, the estimated chance of needing treatment within five years was 8.4% in the low-risk group, 28.4% in intermediate-risk, and 61.2% in high-risk.
Another widely used model, the CLL International Prognostic Index (CLL-IPI), combines age, clinical stage, serum beta-2 microglobulin, IGHV mutation status, and TP53 abnormalities. It was built to predict overall survival and can also estimate time to first treatment.
How Is Treatment Selected Once It Is Required in CLL?
When choosing treatment, disease biology, particularly TP53 status, becomes important alongside age, comorbidities, concomitant medications, and toxicity considerations.
Modern first-line treatment is largely based on targeted therapy: BTK inhibitors and venetoclax-based combinations. BTK inhibitors suppress signaling that CLL cells depend on for survival and proliferation and are generally given continuously until disease progression or unacceptable toxicity. Venetoclax targets the anti-apoptotic protein BCL2 and can be combined with an anti-CD20 antibody, allowing treatment to be given for a defined period.
Cardiovascular disease can influence the choice of a BTK inhibitor, while renal function and the risk of tumor lysis syndrome are especially relevant when starting venetoclax. Patient convenience with continuous oral therapy and the preference for a time-limited regimen can also influence the choice.
You can also read:
FAQ
Can a very high lymphocyte count be safe in CLL?
Sometimes. CLL can produce strikingly high lymphocyte counts without causing symptoms or damaging normal blood-cell production. Doctors therefore pay close attention to how quickly the count is changing, along with hemoglobin, platelets, lymph nodes, spleen size, and symptoms. A high lymphocyte count by itself does not automatically mean treatment is needed.
Can CLL improve on its own without treatment?
CLL can remain stable for long periods, and lymphocyte counts may fluctuate during surveillance. True spontaneous regression, in which the leukemia substantially decreases without CLL-directed treatment, is much less common. Most people on watch and wait have persistent CLL that is being monitored, not disease that has disappeared.
Does watch and wait mean I need frequent CT or PET scans?
Not necessarily. Much of CLL surveillance can be performed through clinical review, physical examination, blood counts, and assessment of symptoms. Imaging may be useful in particular clinical situations, but repeated CT or PET scans are not automatically required simply because someone is being monitored without treatment.
Is it better to get vaccines before CLL treatment begins?
Often, yes. People with CLL can have weaker vaccine responses even before treatment, and some CLL therapies can suppress immune responses further. Current guidance therefore supports addressing recommended vaccinations during active surveillance when possible. Live vaccines generally should not be given to people with CLL.
What symptoms during watch and wait should prompt an earlier appointment?
New or rapidly enlarging lymph nodes, worsening fatigue, unexplained weight loss, persistent fever, drenching night sweats, unusual bleeding or bruising, or recurrent infections deserve medical attention. These symptoms do not automatically mean that CLL has progressed, because infection and other conditions can cause similar problems, but they may justify reassessment.
